No Picture
News

Critics push back on Alzheimer’s Association ad blitz to get Medicare to change its Aduhelm ruling: ‘Dead wrong’

The latest Alzheimer’s Association advertising campaign encourages people to fight. Not against the disease or for more research or treatments, but against the Centers for Medicare and Medicaid Services. More specifically, CMS’ recent reimbursement decision to only pay for Biogen and Eisai’s controversial Alzheimer’s drug Aduhelm for patients in clinical…… Click here to view original post… […]

No Picture
News

STAT+: Pharmalittle: Alzheimer’s patient groups to protest Medicare plan for Biogen drug; cancer combo treatments are questioned

Alzheimer’s patient groups are planning publicity and lobbying campaigns to protest a Medicare coverage proposal they say could delay the use of new drugs for 10 years. Click here to view original post… […]

No Picture
News

Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy,… Click here to view original post… […]